浩欧博(688656) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for the third quarter was ¥102,515,594.03, a decrease of 1.64% compared to the same period last year[4]. - Total profit for the quarter reached ¥14,250,653.99, an increase of 99.61% year-over-year, primarily due to gains from the disposal of an old factory[9]. - Net profit attributable to shareholders was ¥14,019,997.75, reflecting a significant increase of 113.01% compared to the previous year[4]. - The net profit excluding non-recurring gains and losses was ¥6,363,733.15, down 33.93% year-to-date, impacted by tax rate adjustments and increased depreciation expenses[10]. - Basic earnings per share for the quarter were ¥0.22, a 100% increase from the previous year, while diluted earnings per share rose by 120% to ¥0.22[5]. - Total operating revenue for the first three quarters of 2025 was CNY 292,177,576.25, a decrease of 4.4% compared to CNY 307,033,592.46 in the same period of 2024[18]. - Net profit for the first three quarters of 2025 was CNY 26,189,189.19, compared to CNY 26,562,954.15 in the same period of 2024, reflecting a decrease of 1.4%[19]. - Basic earnings per share for the first three quarters of 2025 remained stable at CNY 0.42, while diluted earnings per share decreased to CNY 0.41 from CNY 0.42 in 2024[20]. Assets and Liabilities - Total assets decreased by 6.54% to ¥965,268,588.31 compared to the end of the previous year[5]. - Total assets as of the reporting date were CNY 965,268,588.31, down from CNY 1,032,804,511.08 in the previous period[17]. - Total liabilities decreased to CNY 136,215,244.33 from CNY 220,667,473.27, indicating a significant reduction in financial obligations[16]. - Total equity attributable to shareholders increased to CNY 829,053,343.98 from CNY 812,137,037.81, showing a growth of 2.1%[17]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥57,667,694.62, down 24.47% compared to the previous year[4]. - The company reported a significant increase in cash flow from operating activities, contributing positively to liquidity[20]. - Operating cash inflow for the first three quarters of 2025 was $335.20 million, a slight decrease from $339.74 million in the same period of 2024, reflecting a decrease of approximately 1.5%[21]. - Net cash flow from operating activities for the first three quarters of 2025 was $57.67 million, down 24.5% compared to $76.35 million in 2024[22]. - Cash outflow from investing activities in the first three quarters of 2025 was $65.40 million, significantly lower than $251.90 million in 2024, indicating a reduction of approximately 74%[22]. - Net cash flow from financing activities for the first three quarters of 2025 was -$61.16 million, compared to -$5.61 million in 2024, showing a deterioration in financing cash flow[22]. - The ending cash and cash equivalents balance as of the end of the third quarter of 2025 was $75.38 million, down from $105.13 million at the end of the same period in 2024, a decrease of about 28.3%[22]. - Total cash outflow from operating activities in the first three quarters of 2025 was $277.53 million, compared to $263.38 million in 2024, an increase of about 5.4%[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 3,727[12]. - The largest shareholder, Beijing Huiguang Runkang Pharmaceutical Development Co., Ltd., holds 18,670,878 shares, accounting for 29.41% of total shares[12]. - The second-largest shareholder, Shuangrun Zheng'an Information Consulting (Beijing) Co., Ltd., holds 14,326,151 shares, representing 22.57% of total shares[12]. - The company has not engaged in any share lending or borrowing activities during the reporting period[14]. - There are no significant changes in the top 10 shareholders due to share lending or borrowing activities[14]. - The company has not identified any related party relationships among other shareholders[14]. Research and Development - Research and development expenses totaled ¥11,891,581.57, accounting for 11.60% of revenue, an increase of 0.72 percentage points year-over-year[5]. - Research and development expenses for the first three quarters of 2025 were CNY 33,328,252.53, slightly down from CNY 33,952,496.52 in 2024[19]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters to drive future growth[20].